Gilead Sciences is a pioneer in developing drugs for the treatment of human immunodeficiency virus, liver diseases, hematology/oncology diseases and inflammation/respiratory diseases. The company has a strong HIV franchise with key HIV/AIDS therapies like tenofovir alafenamide based products - Genvoya, Odefsey, Descovy, Biktarvy and Truvada. The portfolio also includes hepatitis C virus drugs like Harvoni and Epclusa and HBV drug. The first cell therapy approved for the treatment of adult patients with relapsed or refractory large B-cell lymphoma, has diversified Gilead's portfolio. Tecartus, another CAR T-cell therapy, was granted an accelerated approval in the United States for the treatment of relapsed or refractory mantle cell lymphoma. The company is also working on diversifying and growing its business beyond antivirals into other therapeutic areas. Gilead is also making inroads in the oncology space with strategic collaborations and acquisitions....
+See More2017-03-15 08:46:00 Wednesday ET

The heuristic rule of *accumulative advantage* suggests that a small fraction of the population enjoys a large proportion of both capital and wealth creatio
2020-05-21 11:30:00 Thursday ET

Most blue-ocean strategists shift fundamental focus from current competitors to alternative non-customers with new market space. W. Chan Kim and Renee Ma
2018-12-23 13:39:00 Sunday ET

The House of Representatives considers a government expenditure bill with border wall finance and therefore sets up a shutdown stalemate with Senate. As fre
2019-02-01 15:35:00 Friday ET

Our proprietary alpha investment model outperforms the major stock market benchmarks such as S&P 500, MSCI, Dow Jones, and Nasdaq. We implem
2019-02-17 14:40:00 Sunday ET

U.S. economic inequality increases to pre-Great-Depression levels. U.C. Berkeley economics professor Gabriel Zucman empirically finds that the top 0.1% rich
2020-04-17 07:23:00 Friday ET

Clayton Christensen defines and delves into the core dilemma of corporate innovation with sustainable and disruptive advances. Clayton Christensen (2000)